Treatment of Cerebral Arteriovenous Malformations With SQUID Liquid Embolic Agent (CHOICE) (CHOICE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03413852|
Recruitment Status : Recruiting
First Posted : January 29, 2018
Last Update Posted : August 9, 2019
|Condition or disease||Intervention/treatment|
|Cerebral Arteriovenous Malformation||Device: SQUID non-adhesive liquid embolic agent|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||111 participants|
|Target Follow-Up Duration:||12 Months|
|Official Title:||Treatment of Cerebral Arteriovenous Malformations With SQUID Liquid Embolic Agent - The CHOICE Study A Non-interventional, Prospective, Single-arm, International, Multicenter Study|
|Actual Study Start Date :||May 11, 2018|
|Estimated Primary Completion Date :||July 2020|
|Estimated Study Completion Date :||August 2021|
- Device: SQUID non-adhesive liquid embolic agent
AVM embolization using SQUID non-adhesive liquid embolic agent
- modified Rankin Score (mRS) [ Time Frame: 3 to 6 months after the last embolisation session ]
mRS is a scale used to measure the degree of handicap or dependence in daily activities of people who have suffered a stroke or other causes of neurological handicap.
The scale ranges from 0 to 6, running from perfect health, without symptoms, to death.
0 - No symptoms
- - No significant disability. Able to carry out all usual activities, despite some symptoms.
- - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
- - Moderate disability. Requires some help, but able to walk unassisted.
- - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
- - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
- - Death.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03413852
|Contact: Laure Coutrotfirstname.lastname@example.org|
|University Hospital Antwerp||Recruiting|
|Contact: Maurits Voormolen, Pr. Dr.|
|Odense University Hospital||Recruiting|
|Contact: Gyula Gal, Dr.|
|Contact: Xavier Barreau, Dr.|
|Contact: Jean-Christophe Gentric, Dr.|
|Hospices Civils de Lyon||Recruiting|
|Contact: Francis Turjman, Prof.|
|Le Kremlin-Bicêtre, France|
|Contact: Laurent Spelle, Prof.|
|Nancy, France, 54000|
|Contact: Serge Bracard, Prof.|
|Paris, France, 75010|
|Contact: Emmanuel Houdart, Prof.|
|Fondation Ophtalmologique Adolphe de Rothschild||Recruiting|
|Paris, France, 75019|
|Contact: Michel Piotin, Dr.|
|Hôpital Maison Blanche||Active, not recruiting|
|Reims, France, 51000|
|Contact: Chrisanthi Papagiannaki, Dr.|
|CHU de Saint-Etienne||Recruiting|
|Saint-Étienne, France, 42000|
|Contact: Mohamed Aggour, Dr.|
|CHU Toulouse||Active, not recruiting|
|Zentralklinikum Augsburg||Not yet recruiting|
|Contact: Ansgar Berlis, Pr. Dr. med.|
|Klinikum der Ruhr-Universität Bochum, Knappschaftskrankenhaus||Not yet recruiting|
|Contact: Werner Weber, Pr. Dr. med.|
|Freiburg, Germany, 79106|
|Contact: Stephan Meckel, Prof. Dr. med.|
|Contact: Markus Möhlenbruch, Dr. med.|
|Klinikum Grosshadern||Not yet recruiting|
|Contact: Franziska Dorn, Dr. med.|
|San Gerardo Monza||Not yet recruiting|
|Contact: Luca Valvassori, Dr.|